NICE adds severe psoriasis treatment to recommended list

Infliximab has been added to the list of recommended treatments for adult psoriasis by NICE.

Under its licence indications, infliximab should only be given in very severe cases, defined as a psoriasis area severity index of 20 or more and dermatology life quality index over 18. 

In its technology appraisal, NICE also says patients need to have a failed response to standard therapies in order to qualify for the treatment. Only those who show an adequate response should receive infliximab beyond 10 weeks.

The immunomodulators efalizumab and etanercept are already recommended by NICE for use in the treatment of severe plaque psoriasis.

On average, the annual cost of infliximab is £11,750 per patient.

rachel.liddle@haymarket.com

NICE guidance for psoriasis

Comment below and tell us what you think 


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus